PTM Wealth Management’s NewAmsterdam Pharma NAMS Stock Holding History

PTM Wealth Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$382K	Hold	12,900	–	–	0.17%	38
2026 Q1	$440K	Hold	12,900	–	–	0.23%	33
2025 Q4	$432K	Hold	12,900	–	–	0.24%	32
2025 Q3	$419K	Hold	12,900	–	–	0.25%	33
2025 Q2	$256K	Buy	+12,900	New	+$235K	0.17%	39

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

PTM Wealth Management's NAMS Position: Q2 2026 in Review

PTM Wealth Management held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 12,900 shares worth $382K. The position accounts for 0.17% of the portfolio, ranked #38.

PTM Wealth Management first reported a position in NAMS in Q2 2025 and has held it in 5 quarters since. The position peaked at $440K in Q1 2026. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

PTM Wealth Management held 12,900 shares of NewAmsterdam Pharma worth $382K as of Q2 2026.
PTM Wealth Management left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up 0.17% of PTM Wealth Management's portfolio in Q2 2026, its #38 holding.
PTM Wealth Management first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 5 quarters since.
PTM Wealth Management's NewAmsterdam Pharma position peaked at $440K in Q1 2026.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on PTM Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.